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INTRODUCTION
The stromal microenvironment plays an important role in prostate
development and prostate cancer progression. Stromal changes
during tumorigenesis have been documented in breast, colon, lung
and prostate tumours (Bhowmick et al., 2004). Tumour stroma
contains activated or carcinoma-associated fibroblasts (CAFs) and
stimulates prostate carcinogenesis (Franco et al., 2011; He et al.,
2007; Kiskowski et al., 2011; Olumi et al., 1999; Orimo et al., 2005;
Tuxhorn et al., 2002). Using tissue recombination and renal capsule
xenografting, human prostate CAFs have been shown to induce
tumour formation from initiated but non-tumorigenic human
prostate epithelial cells (the SV40 immortalised BPH1 cell line),
whereas normal prostate fibroblasts (NPFs) did not (Barclay et al.,
2005; Olumi et al., 1999).
Prostate cancer shows some similarities to embryonic prostate
development, notably the importance of stromal-epithelial
signalling and of paracrine regulation of stromal and epithelial
compartments. Similarities in gene expression between prostate
cancer and development have been documented (Joesting et al.,
2005; Orr et al., 2011). Our gene profiling studies of embryonic
(inductive) prostate mesenchyme identified pathways that are
expressed or dysregulated in prostate cancer, including the delta-
like 1 (Dlk1)/Notch2 and SCUBE1 molecules (Vanpoucke et al.,
2007). WFDC1, which was identified as a growth inhibitor
expressed in fetal urogenital mesenchyme, has been shown to be
downregulated in reactive prostatic stroma (Ressler and Rowley,
2011). Several independent studies have demonstrated the potency
of developmental mesenchyme and microenvironments in
normalising the growth and differentiation of tumour epithelia
(Abbott et al., 2008; Hayashi and Cunha, 1991). Although these
studies have shown how potent the developmental
microenvironment can be in controlling malignant epithelial
growth, there is a poor understanding of the molecular mediators
of this activity.
Dlk1 encodes a transmembrane protein that belongs to the Notch
family, which regulates cell fate decisions and might potentiate or
inhibit cell differentiation depending on cell context (Nueda et al.,
2007). Previously, we showed Notch/Dlk1 signalling plays an
important role in prostate development, regulating stromal survival,
and stromal and epithelial differentiation (Orr et al., 2009).
SCUBE1 is a secreted glycoprotein with epidermal growth factor
repeats and a CUB domain (Grimmond et al., 2000). Studies in
zebrafish suggested that Scube family members are involved in
sonic hedgehog (Shh) signalling (Woods and Talbot, 2005) and
other extracellular signalling pathways (Kawakami et al., 2005).
Previously, we demonstrated SCUBE1 transcript expression is
decreased in patient-matched pairs of CAFs in comparison with
normal prostate fibroblasts (Vanpoucke et al., 2007).
The present study was designed to determine whether we could
use molecules identified in prostate development as the basis for
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SUMMARY
Human prostatic cancer-associated fibroblasts (CAFs) can elicit malignant changes in initiated but non-tumorigenic human prostate epithelium,
demonstrating that they possess pro-tumorigenic properties. We set out to reduce the pro-tumorigenic activity of patient CAFs using the Dlk1 and
SCUBE1 molecules that we had previously identified in prostate development. Our hypothesis was that mesenchymally expressed molecules might
reduce CAF pro-tumorigenic activity, either directly or indirectly. We isolated primary prostatic CAFs and characterised their expression of CAF markers,
expression of Notch2, Dlk1 and SCUBE1 transcripts, and confirmed their ability to stimulate BPH1 epithelial cell proliferation. Next, we expressed
Dlk1 or SCUBE1 in CAFs and determined their effects upon tumorigenesis in vivo following recombination with BPH1 epithelia and xenografting in
SCID mice. Tumour size was reduced by about 75% and BPH1 proliferation was reduced by about 50% after expression of Dlk1 or SCUBE1 in CAFs,
and there was also a reduction in invasion of BPH1 epithelia into the host kidney. Inhibition of Notch signalling, using inhibitor XIX, led to a reduction
in BPH1 cell proliferation in CAF-BPH1 co-cultures, whereas inhibition of Dlk1 in NIH3T3-conditioned media led to an increase in BPH1 growth. Our
results suggest that pro-tumorigenic CAF activity can be reduced by the expression of developmental pathways.
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manipulation of CAF pro-tumorigenicity, and whether these might
be effective in regulating tumour growth. CAFs were modified to
express Dlk1 or to increase expression of SCUBE1. Manipulation
of these pathways led to reduced tumorigenicity in an in vivo model
of prostate cancer.
RESULTS
Isolation and characterisation of cancer-associated fibroblasts
We isolated and characterised CAFs from patients with a prostate
cancer diagnosis undergoing transurethral resection of the prostate.
Tissue sections were analysed using haematoxylin and eosin (H&E)
and Microseminoprotein B (MSMB) staining to confirm the
presence of cancer (supplementary material Fig. S1). RT-PCR
analysis of CAFs confirmed transcript expression of mesenchymal
markers vimentin and fibroblast-specific protein 1 (VIM, FSP1),
smooth muscle markers (CNN1, MYH11), pro-tumorigenic
chemokine CXCL12 (Orimo et al., 2005), reactive stroma protease
fibroblast activated protein (FAP) and androgen receptor
(supplementary material Fig. S2 and Table S1). CAF isolates were
analysed by immunocytochemistry; all showed VIM expression and
CAF subsets showed FSP1, CNN1, SMACT and FAP expression
(Fig. 1A). Fibroblast heterogeneity in cancer stroma in vivo is
documented and consistent with observations by ourselves and
others (Franco et al., 2011; Kiskowski et al., 2011; Orr et al., 2011;
Sugimoto et al., 2006). Similarly, weak or absent E-cadherin
transcript expression and few pan-cytokeratin-positive cells
indicated a low epithelial contamination rate in CAFs at P4,
consistent with other published studies.
To verify that our CAF isolates stimulated epithelial growth, we
confirmed that BPH1 cells proliferated faster in conditioned
medium from CAFs, the effect being modest but significant (Fig.
1B). Similarly, BPH1 cells proliferated faster in co-culture with CAFs
than did BPH1 cells grown in isolation (Fig. 1C). Co-culture of CAFs
with BPH1 cells resulted in a stronger effect on BPH1 proliferation,
suggesting that cell-cell contact might be important.
Our previous studies identified the expression of Dlk1 and
SCUBE1 in embryonic mesenchyme and observed that SCUBE1
was decreased in CAFs (Vanpoucke et al., 2007). We showed that
Dlk1 and Notch signalling was important for mesenchymal survival
and differentiation and important in prostate development (Orr et
al., 2009). By northern blotting analysis we established NOTCH2
expression in CAFs and NPFs, but observed no significant
difference in transcript levels between normal or cancer samples.
DLK1 expression was absent from both CAFs and NPFs (Fig. 1D),
consistent with its predominantly embryonic expression pattern
(Yevtodiyenko and Schmidt, 2006).
Expression of Dlk1 or SCUBE1 reduces pro-tumorigenic activity of
prostate CAFs
We selected four CAF isolates and used lentiviral constructs to
upregulate SCUBE1 or express DLK1 in our CAF isolates. Patient-
matched CAFs not transduced with a lentivirus (no virus), and
CAFs transfected with an LV-emGFP control vector (expressing
green fluorescent protein, GFP), EV, were included as controls.
Successful cell transfection with EV was confirmed by using GFP;
we estimated that about 80-90% of CAFs expressed GFP protein,
72 hours after transfection in culture. Western blot analysis
confirmed successful transduction of CAFs with LV-Dlk1 and LV-
SCUBE1-myc (supplementary material Fig. S3). To study the effects
of DLK1 or SCUBE1 on CAF activity we used a xenograft model
of prostate cancer (Ao et al., 2007; Olumi et al., 1999). Four CAF
isolates were modified with lentivirus to express Dlk1 or to increase
SCUBE1 levels. Un-infected or EV-, Dlk1-LV- or SCUBE1-LV-
infected CAFs were recombined with BPH1 cells in collagen gels
and grafted under the kidney capsule of adult male SCID mice (Fig.
2A). CAFs from three additional patients were infected with Dlk1-
LV (supplementary material Fig. S4).
The gross morphology of the grafts showed that tumours made
using CAFs overexpressing SCUBE1 or expressing Dlk1 showed a
significant decrease (P<0.0001) in volume in comparison with the
control tumours (no virus) and EV-infected CAFs (Fig. 2A,B).
Next, we measured the effect on BPH1 cell proliferation in our
reconstituted tumours, because CAF modification might reduce
BPH1 cell proliferation and account for the decrease in tumour
volume. The xenograft host mice were treated with BrdU prior to
harvesting the tumours, and BPH1 cell proliferation was quantified
by counting BrdU incorporation in SV40T-positive cells (Fig. 2C,
inset). This excluded non-tumour-, host- or patient-derived
epithelia because only BPH1 cells express SV40T. We observed that
tumour volume was relative to BPH1 cell proliferation: larger
tumours demonstrated higher proliferative indices of %BrdU-
positive BPH1-SV40T cells in comparison with smaller tumours.
Also, tumours prepared with CAFs expressing Dlk1 or SCUBE1
were smaller and demonstrated significantly lower (P<0.001) values
of %BrdU-positive BPH1-SV40T cells than control tumours (Fig.
2C). 
Modifying CAFs had an effect on reconstituted tumour size and
BPH1 cell proliferation. To further investigate the mechanism of
action, we tested whether altering Dlk1 or SCUBE1 in CAFs or
BPH1 cells cultured in vitro would affect cell growth. An MTS assay
identified no difference in cell proliferation of BPH1 cells or CAFs
TRANSLATIONAL IMPACT
Clinical issue
The tumour microenvironment, and particularly cancer-associated fibroblasts
(CAFs) within it, are increasingly recognised as playing an important role in the
growth of tumour epithelia and cancer progression. One experimental strategy
for manipulating the tumour microenvironment is to promote programmes
from the embryonic mesenchyme or microenvironment. This approach aims to
normalise the growth and differentiation of tumour epithelia by inducing re-
differentiation. 
Results
The authors previously identified several molecules in developing prostate
mesenchyme. In this study, they set out to determine the effects of these
molecules on prostate CAFs in an in vivo model system of tumour
reconstitution. Their hypothesis was that mesenchymally expressed
developmental regulators might inhibit the pro-tumorigenic activities of CAFs
– either directly or indirectly. Indeed, their data show that expression of Delta-
like 1 (Dlk1, a transmembrane protein of the Notch family) or SCUBE1 (a
secreted glycoprotein) in CAFs reduced tumour size, epithelial growth and
invasion of reconstituted tumours in vivo. 
Implications and future directions
These data suggest that certain mesenchymal secreted regulators of
development could be applied to alter the tumour microenvironment, and
thereby to reduce tumour growth and progression, offering a new avenue to
therapeutic intervention.
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transfected with LV-SCUBE1, LV-Dlk1, EV or no virus
(supplementary material Fig. S5). It has been demonstrated that
expression of cyclin D1 in normal fibroblasts leads to increased
proliferation and acquisition of pro-tumorigenic activity (He et al.,
2007). Because neither Dlk1 or SCUBE1 reduced CAF proliferation,
we conclude that their inhibition of pro-tumorigenic activity was
not mediated by reducing CAF proliferation. Similarly, neither Dlk1
nor SCUBE1 directly inhibited BPH1 proliferation in vitro.
Reduction of invasion in reconstituted tumours containing
modified CAFs
In all CAF-BPH1 tumours, SV40T-positive BPH1 cells were
distributed at the periphery of the tumour and some formed large
nests of cells that pushed against the margin between the tumour
and kidney, consistent with previous studies (Ao et al., 2007; Franco
et al., 2011; Kiskowski et al., 2011) (Fig. 3A). Control tumours (EV-
infected or without virus) recapitulated some of the features of
prostate cancer. E-cadherin expression in SV40T-expressing BPH1
cells had a characteristic cell-surface and cytoplasmic ‘patchy’
distribution pattern (supplementary material Fig. S6A). Also,
infiltrating BPH1 cells at the kidney tumour margin exhibited
Fig. 1. Expression of CAF markers, pro-proliferative CAF activity and Dlk1
and Notch2 mRNAs in CAFs. (A)Immunocytochemical detection of VIM,
FSP1, CNN1, PCK, AR, FAP (green) and SMACT (red) in CAFs. VIM, CNN1 and AR
were expressed in most or all cells in the cultures, whereas SMACT and FAP
were co-expressed in CAF subsets. PCK identified rare epithelial cells in the
CAFs. (B)CAF-conditioned medium (CM) from three CAF lines was collected
and added to BPH1 cells; this elicited a small but statistically significant
increase in BPH1 growth. (C)Co-culture of BPH1 cells with three CAF isolates
produced a significant stimulation of BPH1 growth. (D)Northern blotting was
used to establish the expression of transcripts for DLK1, NOTCH2 and GAPDH in
two pairs of matched CAFs and NPFs. Transcripts for DLK1 were absent,
whereas NOTCH2 was expressed. ***P<0.001, using the Student’s t-test.
Fig. 2. Effect of expression of Dlk1 or SCUBE1 in CAFs on tumour size and
BPH1 cell proliferation after growth in vivo. (A)Gross morphology of
reconstituted CAF-BPH1 tumours (arrows) on host kidney. Patient-matched
CAF isolates (n4) were modified with lentivirus to express Dlk1 or increase
SCUBE1. EV-, Dlk1-LV- or SCUBE1-LV-infected CAFs were recombined with
BPH1 cells to form tumours. EV-CAF tumours were large, whereas those CAFs
infected with Dlk1-LV or SCUBE1-LV appeared smaller. (B)Tumour volume was
measured; infection of CAFs with Dlk1-LV or SCUBE1-LV resulted in a
statistically significant reduction in tumour volume (one-way ANOVA with
post-hoc Dunnett’s test, P<0.001). (C)The proliferation rate of SV40T-BPH1
cells was measured by BrdU incorporation. Inset, immunofluorescent
colocalisation was performed using SV40T and BrdU antibodies. SV40T-
expressing cells (BPH1) were red, BrdU-expressing cells were green and cells
co-expressing SV40T and BrdU were yellow. CAFs infected with Dlk1-LV or
SCUBE1-LV resulted in tumours with lower epithelial (SV40T-BPH1)
proliferation rates and showed a statistically significant difference from
uninfected or EV-infected CAFs (one-way ANOVA with post-hoc Tukey
multiple comparison, b, P<0.001).
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markers of epithelial-mesenchymal transition characterised by
SV40T-positive BPH1 cells mis-expressing the mesenchymal
marker vimentin (supplementary material Fig. S6B). Some tumours
demonstrated SV40T-BPH1 cells crossing the kidney tumour
margin and intermingling with kidney tubules, and these were
classified as invasive (Fig. 3A). In grafts prepared from CAFs from
three patients (infected with empty virus, EV), we determined that
77% (17 of 22 grafts) showed BPH1 cells migrating into the kidney,
forming invasive tumours. In comparison, tumours containing
CAFs modified with LV-Dlk1 or LV-SCUBE1 (Fig. 3B-D) showed
a modest reduction in the proportion of tumours with an invasive
phenotype: LV-Dlk1, 33% (3 out of 9 grafts); and LV-SCUBE1, 59%
(10 out of 17 grafts).
The Notch pathway plays a role in CAF pro-tumorigenic activity
Dlk1 has been shown to function as an inhibitor of the Notch
pathway in Drosophila and mammals (Baladrón et al., 2005; Bray
et al., 2008; Nueda et al., 2007), and expression of Dlk1 in CAFs
led to a decrease in the size of reconstituted tumours. The Notch
pathway has been shown to play a role in prostate development
(Orr et al., 2009) and cancer (Santagata et al., 2004), and we have
used small molecule inhibitors of presenilin and -secretase to
inhibit Notch signalling (although there might be off-target effects).
CAFs, BPH1 cells and co-cultures of CAFs and BPH1 cells were
grown in the presence of a -secretase inhibitor (Notch inhibitor
XIX). Loss of Notch activity had no effect on cell proliferation of
CAF or BPH1 cells when cells were cultured alone (Fig. 4A).
Inhibition of Notch signalling in co-cultures of CAF and BPH1 cells
caused a significant and dose-dependent decrease in BPH1 cell
proliferation but not CAF proliferation (Fig. 4B). Taken together,
the results suggest that loss of Notch signalling in CAFs has an
indirect effect on BPH1 cell proliferation.
To examine the importance of Dlk1 in regulating BPH1
proliferation, we cultured BPH1 cells in the presence of conditioned
medium prepared from NIH3T3 fibroblasts, which express Dlk1.
CAFs do not express Dlk1 (Fig. 2, and unpublished observations).
We observed increased proliferation of BPH1 cells when cultured
in 3T3-conditioned medium. Inhibition of Dlk1 by addition of an
anti-Dlk1 antibody to 3T3-conditioned medium further increased
BPH1 cell proliferation (Fig. 4C). We conclude that Dlk1 can inhibit
BPH1 cell proliferation in the presence of fibroblast-secreted
factors. The cellular microenvironment is important in determining
Notch and Dlk1 activity (Baladrón et al., 2005; Nueda et al., 2007).
In the absence of fibroblast-conditioned medium, Dlk1-LV had no
effect on proliferation of BPH1 cells or CAFs in vitro
(supplementary material Fig. S5).
DISCUSSION
We set out to examine the potential utility of developmental
mesenchymally expressed molecules as inhibitors of tumorigenesis,
via indirect action in CAFs. Our hypothesis was that DLK1 or
SCUBE1 might directly or indirectly reduce pro-tumorigenic CAF
activity by altering CAF homeostasis or differentiation. This was
based upon their proposed role in embryonic mesenchyme.
Embryonic mesenchyme has been shown to affect the
differentiation of rat Dunning tumour (a prostate tumour model)
(Hayashi and Cunha, 1991), whereas malignant melanoma cells can
be normalised by insertion into an embryonic environment (Abbott
et al., 2008). These studies demonstrate the potency and
applicability of re-differentiating tumour cells using embryonic
mesenchyme and developmental signals. However, the precise
identity of the re-differentiating signals is unknown, as is the
importance of their cellular context, ECM availability and the
presence of extracellular inhibitors. We suggest that our studies
have added further support by demonstrating the ability of the
microenvironment and CAFs to regulate tumorigenesis.
We showed that expression of Dlk1 and SCUBE1 in CAFs
reduced their pro-tumorigenic activity, resulting in smaller tumours
with lower epithelial proliferation rates. These molecules are
extracellular and might be used as novel therapeutic inhibitors of
tumorigenesis. We are not aware of other studies using such
signalling pathways to inhibit CAF pro-tumorigenic signalling in
a similar way and suggest the term ‘deCAF’ to denote the partial
or complete inhibition of pro-tumorigenic signalling from CAFs.
We suggest that other molecules expressed within the mesenchymal
compartment during development might have similar or greater
anti-tumorigenic properties, and hope that this paradigm is further
investigated. It will also be important to determine whether our
findings can be confirmed in other tumour types such as breast,
colon, pancreatic and lung – or wherever there is evidence of
significant microenvironmental effects.
Recently, it has emerged that heterogeneity within CAFs is a key
element required for their pro-tumorigenicity (Franco et al., 2011;
Fig. 3. Histology of CAF-BPH1 tumours and evidence of BPH1 invasion
into host kidney. (A-C)Images of a reconstituted tumour prepared from (A)
EV- (empty vector), (B) Dlk1-LV- or (C) SCUBE1-LV-infected CAFs (n4 patients),
plus BPH1 cells. Immunolocalisation of SV40T (brown) shows BPH1 cell
distribution in representative tumour sections at low power (on the left) and
high power (on the right). BPH1 cell invasion into the host kidney was found in
the majority of tumours prepared with CAFs infected with EV. There was a
modest reduction in the proportion of grafts with BPH1 cells (SV40-positive)
invading the kidney in tumours prepared with CAFs infected with EV (77%)
compared with Dlk1-LV (33%) or SCUBE1-LV (59%). Kidney tubules are marked
with asterisks. Scale bars: 500 μm (left) and 50 μm (right).
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Kiskowski et al., 2011). The CAFs used in our studies were
heterogeneous with regard to their expression of FSP1 and SMACT
(Fig. 1), which is a feature of most CAFs (Sugimoto et al., 2006). Few
markers of CAF heterogeneity exist and thus it is not yet possible to
define the extent of CAF heterogeneity. However, it is likely that
molecules that control the heterogeneity of the CAF population could
alter CAF pro-tumorigenic signalling indirectly. For example, any
molecule that reduces CAF heterogeneity but promotes homogeneity
would be predicted to inhibit CAF pro-tumorigenic activity.
Therefore, Dlk1 or SCUBE1 might reduce CAF pro-tumorigenicity
via effects upon CAF differentiation or heterogeneity, but currently
we have no markers with which to test this possibility.
We suggest that Dlk1 might be acting as a Notch inhibitor in our
in vitro and in vivo studies via direct and/or indirect pathways. A
reduction in Notch signalling or increase in Dlk1 expression in CAFs
had similar effects on BPH1 cell proliferation, both causing a
decrease. Other studies have shown that downregulation of Notch
signalling can inhibit prostate cancer cell growth, migration and
invasion, though these are probably direct effects within the epithelial
compartment (Santagata et al., 2004). Also, decreasing Notch
signalling by blocking Notch receptor activation with Dlk1 has been
proposed as an anti-cancer therapy (Dikic and Schmidt, 2010).
We have shown that manipulation of Dlk1 or SCUBE1 expression
in CAFs can be used to reduce CAF-mediated tumour growth and
invasion. The results of studies on patient-derived primary CAFs
in xenografts in vivo support the idea that our approach might work
in patients, because our studies are based upon primary non-
immortalised cells. However, the epithelial cells in our model system
are SV40T immortalised and it will be important to extend this
work into a model system using both patient tumour epithelia as
well as CAFs. This will be a substantial undertaking, given the
difficulties associated with culture and propagation of primary
tumour epithelia. This notwithstanding, we hope that the use of
developmental mesenchymal pathways might become a general
therapeutic target for novel anti-tumour molecules.
MATERIALS AND METHODS
CAF isolation and cell line culture
CAFs were isolated from human transurethral resection of the
prostate samples from patients with a cancer diagnosis undergoing
surgery at the Western General Hospital, Edinburgh (ethical
approval MREC 02/5/63) as previously described (Olumi et al.,
1999; Orr et al., 2011). Informed consent was obtained from all
CAF donors. Cells were seeded at 2×103 cells per well in 96-well
plates (for growth assays) or at 75×104 cells in a 75-cm2 flask. All
cell culture experiments were performed in triplicate wells on at
least two replicate experiments.
Preparation and use of conditioned medium
CAFs or NIH3T3s were plated in 75-cm2 flasks and grown
overnight. Medium was replaced with serum-free DMEM and
incubated for 24 hours. The medium was then collected,
centrifuged to remove cell debris, passed through a 0.45 μm filter
and stored at −80°C. BPH1 cells were incubated in serum-free
medium for 24 hours prior to addition of CAF-conditioned
medium. Cell growth was measured by MTS assay after 72 hours.
Co-culture of CAF and BPH1 cells
CAF cells were seeded 5×104 in six-well plates and BPH1 cells were
added at 2×104 cells/well with CAFs or at 7×104 cells/well without.
Cells were washed in PBS and co-cultured in serum-free medium
for 72 hours. To examine loss of Notch signalling, cells were
incubated in serum-free medium for 24 hours prior to addition of
0.5 or 1.5 μM Notch inhibitor XIX (Calbiochem, Nottingham, UK)
in 1% serum medium or equal volume of vehicle (20% DMSO in
ethanol). Cells were cultured for 72 hours and then incubated with
Fig. 4. Effect of inhibition of Notch signalling on CAF-BPH1 interactions in
vitro, and inhibition of Dlk1 signalling in NIH3T3-conditioned medium
upon BPH1 proliferation. (A)MTS cell number assay of BPH1 cells or CAFs
cultured individually with different concentrations of Notch inhibitor XIX (NI).
Addition of Notch inhibitor XIX had no effect on either BPH1 or CAF growth
when cultured individually. (B)BrdU incorporation into BPH1 cells cultured in
the presence or absence of CAFs and with or without Notch inhibitor XIX.
Addition of Notch inhibitor led to a statistically significant decrease in BPH1
proliferation (black bars) (one-way ANOVA with Tukey multiple comparison, b
c, d, P<0.001) but no effect on CAF proliferation (white bars). (C)MTS assay of
BPH1 cells cultured in NIH-3T3-conditioned medium, with addition of goat IgG
or anti-Dlk1 antibody. BPH1 cell proliferation increased significantly in the
presence of NIH-3T3-conditioned medium and cell proliferation increased
further with addition of anti-Dlk1 antibody (one-way ANOVA with Tukey
multiple comparison, b, c, P<0.001).
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BrdU (100 μg/ml) for 2 hours prior to fixation. CAFs and BPH1
cells were treated with 0.2, 0.5 or 1.5 μM Notch inhibitor XIX and
growth was measured by MTS assay after 72 hours.
Cell culture with 3T3-conditioned medium and Dlk1 antibody
BPH1 cells were cultured in serum-free medium for 24 hours prior
to addition of NIH3T3-conditioned medium and/or goat IgG or
Dlk1 antibody (0.5 or 1 μg/ml) (Santa Cruz Biotechnology, Santa
Cruz, CA).
MTS cell assay
Cell number was measured using the Cell Titer 96 AQueous One
Solution Cell Proliferation Assay (Promega UK, Southampton, UK).
Cell Titer Solution was added to the cells in culture medium at a
ratio of 1:6 and incubated at 37°C for 100 minutes followed by
absorbance reading at 490 nm.
Cell infection with lentivirus
CAFs and BPH1 cells were seeded and, after 24 hours, cells were
infected with lentivirus-containing media (EV, Dlk1-LV and
SCUBE1-LV) with 0.6 μg/ml polybrene (Sigma-Aldrich, Dorset,
UK).
Kidney capsule xenografts
Cell recombinants were prepared by mixing 100,000 epithelial
(BPH1) cells with 250,000 CAFs in neutralised rat tail collagen
prepared as described previously (Ao et al., 2007; Olumi et al., 1999).
Recombinants were then grafted beneath the renal capsule of adult
male SCID mice. Three months after grafting, hosts were sacrificed;
BrdU was injected 2 hours before sacrifice and kidneys were excised
and photographed. The graft dimensions were measured and
tumour volume was calculated using the ellipsoidal formula:
volume  width2 × length × 0.52, as described (Ao et al., 2007).
Note that this formula underestimates the volume of large invasive
tumours compared with smaller non-invasive tumours. Grafts were
fixed in 10% formalin, embedded in paraffin and processed for
immunohistochemistry.
Northern blotting analysis
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Crawley, UK) as per the manufacturer’s instructions. Northern
blotting for DLK1, NOTCH2 and GAPDH was performed as
described previously (Orr et al., 2009; Vanpoucke et al., 2007).
Immunohistochemistry
Histology of xenograft sections was examined by H&E staining.
For immunostaining, sections were pressure-cooked in 10 mM
citric acid, pH 6.0, for 5 minutes. Immunohistochemistry with DAB
was performed using the Vision Biosystems Bond Immunostaining
Robot using a secondary polymer (Leica Microsystems Wetzlar,
Germany). Cells on chamber slides or six-well plates were fixed in
methanol and acetone (1:1); antigen retrieval of nuclear protein or
BrdU was performed by pre-treatment with 2M HCl. For
fluorescent immunolocalisation in cells and antigen co-localisation,
antibodies were visualised with species conjugated with either Alexa
Fluor 488 or Alexa Fluor 546 (Molecular Probes, Eugene, OR), as
appropriate. DAPI (Sigma-Aldrich, Dorset, UK) was used as a
counterstain. To calculate the proliferation index, confocal images
of sections of xenografts stained for BrdU and SV40T at 40×
magnification were used to measure BrdU incorporation into BPH1
cells, as SV40T is a marker of BPH1 cells. The BrdU proliferation
index was measured by cell counting of at least three confocal
images of each xenograft, and calculated as the number of BrdU-
and SV40T-positive cells as a percentage of the total number of
SV40T cells. Statistical analysis was performed using Graphpad
Prism software (San Diego, CA).
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